SCHEMBL6845463

SCHEMBL6845463

Cc1ccc(-n2ccc3cc(-c4cccnc4)ccc32)cn1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 8/20 0.55
CYP11B1 P15538 7/20 0.55
CYP19A1 P11511 4/20 0.46
CYP17A1 P05093 3/20 0.46
HTR1D P28221 1/20 0.44
GRM2 Q14416 1/20 0.43
NTSR1 P30989 1/20 0.43
DGAT1 O75907 1/20 0.42
MAPT P10636 1/20 0.41
FGFR1 P11362 1/20 0.41
ALOX5AP P20292 1/20 0.41
CYP2A6 P11509 1/20 0.40
PTGS2 P35354 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA3 P34903 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6682744 0.91 CYP11B2 (0.50) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL6846125 0.86 CYP11B2 (0.59) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL6657591 0.84 CYP11B2 (0.56) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL6966876 0.83 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL6658922 0.82 CYP17A1 (0.41) CYP11B2CYP11B1CYP19A1CYP17A1DGAT1
SCHEMBL16356718 0.82 CYP11B2 (0.56) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL6657515 0.81 CYP11B2 (0.54) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL22515743 0.81 CYP11B2 (0.53) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D
SCHEMBL6656915 0.81 CYP11B1 (0.50) CYP11B2CYP11B1CYP19A1CYP17A1NTSR1
SCHEMBL6663687 0.80 CYP11B2 (0.49) CYP11B2CYP11B1CYP19A1CYP17A1HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 CYP11B2 53/4885CYP11B1 30/4885CYP19A1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.